TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A South Asian physician describes being screened for diabetes under a BMI threshold of 23 but not qualifying for a GLP-1 prescription under the BMI thresholds commonly used for coverage. Her October 31 opinion article argues that clinical guidance and payer rules apply different definitions of obesity to Asian patients; the individual coverage decision and broader policy response are not independently documented in the supplied material.
South Asian physician Hamayle Saeed says her doctor began diabetes screening when her BMI passed 23, but she was told she did not meet the BMI criteria for a GLP-1 drug at 26.5 without diabetes or another qualifying condition. In an October 31 opinion article for MedPage Today, Saeed argues that the difference between screening guidance and drug-coverage rules can leave Asian patients identified as at risk but unable to qualify for treatment under thresholds commonly used by insurers.
Saeed writes that American Diabetes Association guidance calls for diabetes screening at lower BMI levels for Asian Americans, reflecting the risk of developing diabetes at lower body weights. She says her own screening began after her BMI passed 23. She describes her BMI as 26.5 and says she does not have diabetes. Under the eligibility criteria she cites, adults generally qualify for FDA-approved GLP-1 weight-management treatment at a BMI of 30 or higher, or at 27 or higher with a weight-related condition. She says she met neither threshold.
The article also points to a contraction in public coverage for GLP-1 drugs prescribed for weight loss. Saeed says Medi-Cal dropped coverage in January and MassHealth followed in July. The supplied report does not include statements from either program or explain the details, exceptions, or current status of those coverage policies.
Saeed cites research on trial eligibility and treatment outcomes as evidence that standard BMI cutoffs may exclude Asian patients. She describes a 2026 analysis of 352 GLP-1 trials in which BMI criteria sharply reduced the proportion of Asian and Korean adults eligible compared with non-Asian American adults. She also cites the 2025 STEP 11 trial, conducted in South Korea and Thailand, and a post hoc analysis of participants starting below BMI 30. These studies are presented in her article; the supplied material does not include full study documents or independent verification.
Screening Rules Outpace Drug Access
The mismatch matters because a screening threshold and a treatment-coverage threshold serve different purposes, yet patients may experience them as conflicting decisions about the same health risk. A lower threshold can prompt clinicians to check for diabetes while an insurer’s higher BMI requirement can still block coverage for a weight-management drug. Saeed’s account makes that gap concrete, but it does not establish how often patients encounter the same outcome.
The issue also affects how evidence is generated and used. If trials enroll fewer Asian participants because of BMI entry criteria, the resulting evidence may be less representative of those populations. Saeed argues that this can reinforce existing eligibility rules: evidence from trials using higher cutoffs informs product labeling and payer forms, while patients below those cutoffs remain less visible in the research base.
For readers, the distinction is practical: being eligible for diabetes screening does not itself establish eligibility for a GLP-1 prescription or insurance coverage. Eligibility can depend on the drug, its approved use, a patient’s health conditions, the prescriber’s judgment, and the insurer’s policy. The article calls attention to a policy debate, not a change in coverage announced by regulators or insurers.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Garmin Forerunner 70 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
How BMI Thresholds Diverge
BMI is a calculation based on height and weight; it does not directly measure body fat or where fat is carried. Saeed cites research indicating that Asian people may have more visceral fat and less muscle, on average, than people of European descent at the same BMI. She also cites World Health Organization action points of 23 and 27.5 for Asian populations and a study of nearly 1.5 million adults in England that estimated diabetes-risk-equivalent BMI levels of 23.9 for South Asian adults and 26.9 for Chinese adults compared with white adults at BMI 30.
The article says that, in June 2026, the ADA released Asian-specific waist and BMI thresholds for diagnosing obesity, and that its 2026 Standards of Care call for ethnicity-appropriate cutoffs when assessing excess adiposity. Saeed contrasts those clinical developments with US payer forms that, she says, continue to use BMI values of 30 and 27. She also cites UK guidance that lowers the BMI threshold by 2.5 units for several ethnic groups when considering tirzepatide, while setting a different base threshold.
Saeed notes that current US labels for Wegovy and Zepbound describe eligibility using terms such as obesity or overweight with a weight-related condition, without stating a BMI number in the indication wording. She argues that numerical cutoffs can nonetheless persist in trial criteria and prior-authorization requirements. The supplied material does not include the full label language, insurer forms, or agency guidance needed to assess each policy independently.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, MD, in MedPage Today
Coverage Details Remain Unverified
The account is an opinion article based partly on Saeed’s personal experience, not a report of a newly announced national policy or a documented insurer decision reviewed independently. The supplied source does not identify the clinician, insurer, exact drug requested, prior-authorization form, or reason given for the denial. It is also unclear whether Saeed’s case involved an insurer rule, prescribing judgment, or both.
The material does not provide responses from the ADA, FDA, Medi-Cal, MassHealth, or drug manufacturers. It does not spell out which patients or plans were affected by the reported state coverage changes, whether exceptions remain available, or whether payer criteria have since changed. Nor does the source establish that the cited trial findings would, on their own, change a drug’s approved use or require insurers to cover it.
Watch for Policy and Payer Changes
The next developments to watch are whether insurers revise prior-authorization rules, whether state programs clarify or alter GLP-1 coverage, and whether clinical organizations issue more explicit guidance connecting ethnicity-specific obesity definitions to treatment decisions. The supplied source reports no pending rule, scheduled vote, or announced policy change, so no specific decision date is available.
Patients weighing treatment can ask their clinician and health plan which indication and eligibility criteria apply to the particular medication and whether an appeal or exception process exists. A screening recommendation does not guarantee a prescription or coverage; decisions require individual clinical review and confirmation of current plan rules.
Key Questions
Why was diabetes screening discussed at BMI 23?
Saeed says ADA guidance uses a lower BMI threshold for diabetes screening in Asian Americans because diabetes risk can arise at lower body weights. Screening guidance is separate from criteria for prescribing or covering a weight-management drug.
What BMI thresholds did Saeed say blocked GLP-1 eligibility?
She cites thresholds of BMI 30 or higher, or 27 or higher with a weight-related condition, and says her BMI was 26.5 without diabetes. Actual eligibility depends on the medication, its use, clinical circumstances, and the applicable coverage policy.
Does a lower diabetes-screening threshold guarantee GLP-1 coverage?
No. A screening recommendation does not itself establish eligibility for a prescription or insurance reimbursement. The source describes a gap between the screening guidance and the coverage criteria Saeed encountered.
Did insurers or government programs announce a new policy in this report?
No new announcement is documented in the supplied material. Saeed says Medi-Cal ended weight-loss GLP-1 coverage in January and MassHealth followed in July 2026, but the source does not provide program statements or detailed policy terms.
Source: medpagetoday.com
